For patients and members of the public:
Ranibizumab▼
Overview
▼ Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. The Patient Information Leaflet for products containing Ranibizumab from Teva can be downloaded below, along with other information such as Frequently Asked Questions where applicable. To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.
Available as
- Solution for Injection
Date of preparation: June 2022
Reference: COB-GB-NP-00077
Date of preparation: June 2022
Reference: COB-GB-00006